Page 5 of 8, showing 50 records out of 368 total, starting on record 201, ending on 250
| Publication |
Category |
Year |
|
13. Tenta, R., Katopodis, H., Chatzïioannou, A., Pilalis, E., Calvo, E., Luu-The, V., Labrie, F., Kolisis, F., Koutsilieris, M. (2007) Microarray analysis of survival pathways in human PC-3 prostate cancer cells. Cancer Genomics Proteomics, 4: 309-18. |
Prostate Cancer |
2007 |
|
43. Tavtigian, S.V., Simard, J., Teng, D.H.F., Abtin, V., Baumgard, M., Beck, A., Camp, N.J., Carillo, A.R., Chen, Y., Dayananth, P., Desrochers, M., Dumont, M., Farnham, J.M., Frank, D., Frye, C., Ghaffari, S., Gupte, J.S., Hu, R., Iliev, D., Janecki, T., Kort, E.N., Laity, K.E., Leavitt, A., Leblanc, G., McArthur-Morrison, J., Pederson, A., Penn, B., Peterson, K.T., Reid, J.E., Richards, S., Schroeder, M., Smith, R., Snyder, S.C., Swedlund, B., Swensen, J., Thomas, A., Tranchant, M., Woodland, A.-M., Labrie, F., Skolnick, M.H., Neuhausen, S., Rommens, J., Cannon-Albright, L.A. (2001) A candidate prostate cancer susceptibility gene at chromosome 17p. Nat. Genet., 27: 172-180. |
Prostate Cancer |
2001 |
|
12. Takase, Y., Luu-The, V., Poisson-Paré, D., Labrie, F., Pelletier, G. (2007) Expression of sulfotransferase 1E1 in human prostate as studied by in situ hybridization and immunocytochemistry. Prostate, 67: 405-409. |
Prostate Cancer |
2007 |
|
18. Takase, Y., Lévesque, M.H., Luu-The, V., El-Alfy, M., Labrie, F., Pelletier, G. (2006) Expression of enzymes involved in estrogen metabolism in human prostate. J.Histochem Cytochem., 54: 911-21. |
Prostate Cancer |
2006 |
|
79. Têtu, B., Van der kwast, T., Fradet, Y., Candas, B., Gomez, J.L., Cusan, L., Labrie, F. (1998) Morphologic effects of neoadjuvant hormone therapy on prostate cancer. Mol. Urol., 2: 103-107. |
Prostate Cancer |
1998 |
|
163. Têtu, B., Srigley, J.R., Boivin, J.C., Dupont, A., Monfette, G., Pinault, S., Labrie, F. (1991) Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma: a histopathologic and immunohistochemical study. Am. J. Surg. Pathol., 15: 111-120. |
Prostate Cancer |
1991 |
|
11. Swanson, C., Mellström, D., Lorentzon, M., Vanderput, L., Jakobsson, J., Rane, A., Karlsson, M., Ljunggren, O., Smith, U., Eriksson, A.E., Bélanger, A., Labrie, F., Ohlsson, C. (2007) The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men. J Clin Endocrinol Metab, 92: 4878-4882. |
Prostate Cancer |
2007 |
|
10. Suzuki, K., Nishiyama, T., Hara, N., Yamana, K., Takahashi, K., Labrie, F. (2007) Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer. Prostate Cancer Prostatic Dis., 10: 301-6. |
Prostate Cancer |
2007 |
|
120. Sun, S., Narod, S., Aprikian, A., Ghadirian, P., Labrie, F. (1995) Androgen receptor and familial prostate cancer. Nature Medicine, 1: 848-849. |
Prostate Cancer |
1995 |
|
130. Sugimoto, K., Simard, J., Veilleux, R., Haagensen, D.E., Labrie, F. (1994) Inverse relationships between cell proliferation and basal or androgen-stimulated apolipoprotein D secretion in LNCaP human prostate cancer cells. J. Steroid Biochem. Mol. Biol., 51: 167-174. |
Prostate Cancer |
1994 |
|
4683. Spitz, I.M., Chertin, B., Fridmans, A., Farkas, A., Bélanger, A., Hartman, H., Labrie, F. (2009). Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists. Prostate Cancer Prostatic Dis, 12: 100-103. |
Prostate Cancer |
2009 |
|
54. Singh, R., Eeles, R.A., Durocher, F., Simard, J., Edwards, S., Badzioch, M., Kote-Jarai, Z., Teare, D., Fortd, D., Dearnaley, D., Ardern-Jones, A., Murkin, A., Dowe, A., Shearer, R., Kelly, J., Labrie, F., Easton, D., Narod, S.A., Tonin, P.N., Foulkes, W.D. (2000) High risk genes predisposing to prostate cancer development-do they exist? Prostate Cancer Prostatic Dis., 3: 241-247. |
Prostate Cancer |
2000 |
|
162. Simard, J., Veilleux, R., de Launoit, Y., Haagensen, D.E., Labrie, F. (1991) Stimulation of apoliprotein D secretion by steroids coincide with inhibition of cell proliferation in LNCaP prostate cancer cells. Cancer Res., 51: 4336-4341. |
Prostate Cancer |
1991 |
|
90. Simard, J., Singh, S.M., Labrie, F. (1997) Comparison of in vitro effects of the pure antiandrogens OH-Flutamide, Casodex and Nilutamide on androgen-sensitive parameters. Urology, 49: 580-589. |
Prostate Cancer |
1997 |
|
89. Simard, J., Labrie, F. (1997) Recent advances in androgen receptor research: relative potencies of pure antiandrogens and implications for prostate cancer therapy, in: New diagnostic and treatment modalities in prostate cancer, Project in Knowledge, pp 15-23. |
Prostate Cancer |
1997 |
|
29. Simard, J., Dumont, M., Soucy, P., Labrie, F., Tavtigian, S.V. (2004) Prostate Cancer Susceptibility Genes, in: Labrie, F. et Koutsilieris, M., eds: Prostate Cancer: Understanding the pathophysiology and re-designing a therapeutic approach, Athens, Greece, Paschalidis Medical Publications, pp 1-38. |
Prostate Cancer |
2004 |
|
32. Simard, J., Dumont, M., Labuda, D., Sinnett, D., Meloche, C., El Alfy, M., Berger, L., Lees, E., Labrie, F., Tavtigian, S.V. (2003) Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocrine Related Cancer, 10: 225-259. |
Prostate Cancer |
2003 |
|
4708. Samson, M., Labrie, F., Zouboulis, C.C., Luu-The, V. (2010) Biosynthesis of dihydrotestosterone by a pathway that does not require testosterone as intermediate in the SZ95 sebaceous gland cell line. J Invest Derm. 130:602-604 |
Prostate Cancer |
2010 |
|
9. Roy, J., Breton, R., Martel, C., Labrie, F., Poirier, D. (2007) Chemical synthesis and biological activities of 16alpha-derivatives of 5alpha-androstane-3alpha, 17beta-diol as antiandrogens. Bioorg Med Chem, 15: 3003-3018. |
Prostate Cancer |
2007 |
|
177. Rousseau, L., Couture, M., Dupont, A., Labrie, F., Couture, N. (1990) Effect of combined androgen blockade with an LHRH agonist and Flutamide in one severe case of male exhibitionism. Can. J. Psychiatry, 35: 338-341. |
Prostate Cancer |
1990 |
|
42. Roach III, M.J., Thrasher, J.B., Blasko, J., Raben, D., Stone, N., Katz, A., Labrie, F. (2001) Prostatectomy, brachytherapy, intensity modulated radiotherapy, hormonal-radiotherapy, salvae cryosurgery and the role of combined hormonal blokade in the treatment of prostate cancer. Reviews in Urology, 3: S49-S58. |
Prostate Cancer |
2001 |
|
28. Qiu, W., Zhou, M., Labrie, F., Lin, S.-X. (2004) Crystal structures of the multi-specific 17beta-hydroxysteroid dehydrogenase type 5: Critical androgen regulation in human peripheral tissues. Mol Endocrinol, 18: 1798-1807. |
Prostate Cancer |
2004 |
|
53. Prostate Cancer Triallist’ Collaborative Group; (2000) Maximum androgen blockade in advanced prostate cancer: an overvierw of the randomised trials. Lancet, 355: 1491-1498. |
Prostate Cancer |
2000 |
|
154. Pinault, S., Têtu, B., Gagnon, J., Monfette, G., Dupont, A., Labrie, F. (1992) Transrectal ultrasound evaluation of local prostate cancer in patients treated with LHRH agonist and in combination therapy with flutamide. Urology, 39: 254-261. |
Prostate Cancer |
1992 |
|
176. Pinault, S., Fortin, D., Gagnon, J., Têtu, B., Dupont, A., Labrie, F. (1990) La biopsie prostatique transrectale sous guide ultrasonore. Radiologie, 10: 313-317. |
Prostate Cancer |
1990 |
|
17. Perreira De Jésus, K., Côté, P.L., Cantin, L., Blanchet, J., Labrie, F., Breton, R. (2006) Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Science: a publication of the Protein Society, 15: 987-99. |
Prostate Cancer |
2006 |
|
41. Pelletier, G., Luu-The, V., El Alfy, M., Li, S., Labrie, F. (2001) Immunoelectron microscopic localization of 3beta-hydroxysteroid dehydrogenase and type 5 17beta-hydroxysteroid dehydrogenase in the human prostate and mammary gland. J. Mol. Endocrinol., 26: 11-19. |
Prostate Cancer |
2001 |
|
52. Pelletier, G., Labrie, C., Labrie, F. (2000) Localization of oestrogen receptor alpha oestrogen receptor beta and androgen receptors in the rat reproductive organs. J. Endocrinol., 165: 359-370. |
Prostate Cancer |
2000 |
|
146. Normand, T., Narod, S., Labrie, F., Simard, J. (1993) Detection of polymorphisms in the estradiol 17β-hydroxysteroid dehydrogenase II gene at the human EDH17B2 locus on 17q11-q21. Hum. Mol. Genet., 2: 479-483. |
Prostate Cancer |
1993 |
|
119. Narod, S., Dupont, A., Cusan, L., Diamond, P., Gomez, J.L., Suburu, R., Labrie, F. (1995) The impact of family history on early detection of prostate cancer. Nature Medicine, 1: 99-101. |
Prostate Cancer |
1995 |
|
145. Martel, C., Trudel, C., Couet, J., Labrie, C., Bélanger, A., Labrie, F. (1993) Blockade of androstenedione-induced stimulation of androgen-sensitive parameters in the rat prostate by combination of Flutamide and 4-MA. Mol. Cell. Endocrinol., 91: 43-49. |
Prostate Cancer |
1993 |
|
153. Martel, C., Trudel, C., Couet, J., Labrie, C., Bélanger, A., Labrie, F. (1992) Blockade of androgen action by combined treatment with a pure antiandrogen (Flutamide) and a 5α-reductase inhibitor (4-MA), in: Giuliani, L. et Puppo, P., eds: Urology, Bologna, Monduzzi Editore, pp 605-610. |
Prostate Cancer |
1992 |
|
4. Ma, C., Yoshioka, M., Boivin, A., Belleau, P., Gan, L., Takase, Y., Labrie, F., St-Amand, J. (2008) Prostate specific genes and their regulation by dihydrotestosterone. Prostate, 68: 241-254. |
Prostate Cancer |
2008 |
|
4687. Ma, C., Yoshioka, M., Boivin, A., Belleau, P., Gan, L., Takase, Y., Labrie, F., St-Amand, J. (2008) Erratum: Prostate specific genes and their regulation by dihydrotestosterone. Prostate, 68: 1372. |
Prostate Cancer |
2008 |
|
3. Luu-The, V., Bélanger, A., Labrie, F. (2008) Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab, 22: 207-221. |
Prostate Cancer |
2008 |
|
105. Luo, S., Martel, C., Leblanc, G., Candas, B., Singh, S.M., Labrie, C., Simard, J., Bélanger, A., Labrie, F. (1996) Relative potencies of flutamide and casodex: preclinical studies. Endocrine-Related Cancer, 3: 229-241. |
Prostate Cancer |
1996 |
|
88. Luo, S., Chen, C., Labrie, C., Candas, B., Singh, S.M., Labrie, F. (1997) Daily dosing with Flutamide or Casodex exerts maximal antiandrogenic activity. Urology, 50: 913-919. |
Prostate Cancer |
1997 |
|
118. Li, X., Singh, S.M., Lourdusamy, M., Mérand, Y., Veilleux, R., Labrie, F. (1995) Synthesis and in vitro antiandrogenic activity of 17beta-hydroxy-17beta-(w-hydroxy/haloalkyn-1'-yl)-4-methyl-4-aza-3-oxo-5beta-androstan-(1-ene)-3-ones. Bioorg. Med. Chem. Lett., 5: 1061-1064. |
Prostate Cancer |
1995 |
|
117. Li, X., Singh, S.M., Labrie, F. (1995) Synthesis and in vitro activity of 17beta-(N-alkyl)formamido/ alkylamido-4-aza-/4-methyl-4-aza-3-oxo-5beta-androstan-3-ones as inhibitors of human 5alpha-reductase and antagonists on the androgen receptor. J. Med. Chem., 38: 1158-1173. |
Prostate Cancer |
1995 |
|
116. Li, X., Singh, S.M., Côté, J., Laplante, S., Veilleux, R., Labrie, F. (1995) Synthesis and in vitro evaluation of 4-substituted-N-(1,1-dimethylethyl)-3-oxo-4-androsten-17beta-carboxamides as 5alpha-reductase inhibitors and antiendrogens. J. Med. Chem., 38: 1456-1461. |
Prostate Cancer |
1995 |
|
8. Levesque, M.H., El-Alfy, M., Berger, L., Labrie, F., Labrie, C. (2007) Evaluation of AIbZIP and Cdc47 as Markers for Human Prostatic Diseases. Urology, 69: 196-201. |
Prostate Cancer |
2007 |
|
87. Laverdiere, J., Gomez, J.L., Cusan, L., Suburu, R.E., Diamond, P., Lemay, M., Candas, B., Fortin, A., Labrie, F. (1997) Beneficial effect of combination therapy administered prior to, during and following external beam radiation therapy in localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 37: 247-252. |
Prostate Cancer |
1997 |
|
175. Lacoste, D., Candas, B., Normand, M., Labrie, F. (1990) Model of the distribution and metabolism of a GnRH superagonist in dogs. Am. J. Physiol., 258: E468-E475. |
Prostate Cancer |
1990 |
|
174. Lacoste, D., Bélanger, A., Labrie, F. (1990) Biosynthesis and degradation of androgens in human prostatic cancer cell lines. In: Bradlow, H., Castagnetta, L., d'Aquino, S. et Labrie, F., eds. Steroid Formation, Degradation and Action in Peripheral Tissues Normal and Neoplastic Tissues. Ann. New York Acad. Sci. pp 389-391. |
Prostate Cancer |
1990 |
|
86. Labrie, F., Simard, J., Singh, S.M., Candas, B. (1997) Estimated potency of Casodex: A problematic design [Letter to the Editor re Schellhammer et al. 45: 745-52, 1995]. Urology, 50: 309-313. |
Prostate Cancer |
1997 |
|
85. Labrie, F., Simard, J., Candas, B. (1997) Reply by the authors to: Editorial comment of: Comparison of in vitro effects of the pure antiandrogens OH-Flutamide, Casodex and Nilutamide on androgen-sensitive parameters [Reply to the authors/P.F. Schellhammer]. Urology, 49: 586-589. |
Prostate Cancer |
1997 |
|
129. Labrie, F., Simard, J., Bélanger, A., Luu-The, V., Labrie, C. (1994) Molecular biology of the intracrine steroidogenic enzymes in the human prostate, in: Motta, M. et Serio, M., eds: Sex Hormones and Antihormones in Endocrine-Dependent Pathology: Basic and Clinical Aspects, New York, Elsevier, pp 77-92. |
Prostate Cancer |
1994 |
|
51. Labrie, F., Luu-The, V., Lin, S.-X., Simard, J., Labrie, C., El-Alfy, M., Pelletier, G., Bélanger, A. (2000) Intracrinology: role of the family of 17beta-hydroxysteroid dehydrogenases in human physiology and disease. J. Mol. Endocrinol., 25: 1-16. |
Prostate Cancer |
2000 |
|
50. Labrie, F., Luu-The, V., Lin, S.-X., Simard, J., Labrie, C. (2000) Role of 17beta-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues. Trends Endocrinol. Metab., 11: 421-427. |
Prostate Cancer |
2000 |
|
40. Labrie, F., Luu-The, V., Labrie, C., Simard, J. (2001) DHEA and its transformation into androgens and estrogens in peripheral target tissues: Intracrinology. Neuroendocrinologie, 22: 185-212. |
Prostate Cancer |
2001 |